Physician profile
Stella Ilyayeva
NPI 1619082625
$219,095.81
in general payments reported to CMS, 2019-2025
76 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85K · 2020: $21K · 2021: $33K · 2022: $14K · 2023: $28K · 2024: $16K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Food and Beverage: $18K · Consulting Fee: $4,675 · Travel and Lodging: $1,737 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,706.25 |
| Food and Beverage | $18,296.53 |
| Consulting Fee | $4,675.00 |
| Travel and Lodging | $1,737.14 |
| Education | $134.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $115,493.86 | 2019-2025 | Evenity, Tepezza, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27,801.59 | 2019-2025 | Jardiance, Synjardy |
| Mannkind Corporation | $22,259.16 | 2019-2025 | Afrezza, V-Go |
| Astrazeneca Pharmaceuticals LP | $19,221.10 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $8,102.50 | 2019-2023 | Verquvo, Steglatro |
| Lilly USA, LLC | $5,208.60 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $2,588.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,500.33 | 2019-2025 | |
| Medtronic, INC. | $1,315.17 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Sanofi-Aventis U.S. LLC | $1,307.10 | 2019-2025 | |
| Corcept Therapeutics | $1,287.10 | 2024-2025 | Korlym |
| Horizon Therapeutics Plc | $1,219.52 | 2019-2023 | Tepezza, Krystexxa |
| Abbott Laboratories | $930.84 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Xeris Pharmaceuticals, INC. | $870.76 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $817.68 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stella Ilyayeva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.